Benefit
Triamcinolone acetonide that has been embedded in a PLGA hydrogel, is known as Zilretta and received its FDA approval in 2017 for treatment of knee osteoarthritis. This formulation is delivered by intra-articular injection to reduce knee osteoarthritis pain, but its overall positive effects are still under investigation. In spite of benefits shown in clinical trials, Zilretta gave no substantial superior benefit compared with immediate release triamcinolone in a clinical trial. In clinical studies, 32 mg of Zilretta was given to 424 patients consisting of 143 patients aged 65 or more and showed that the adverse effects of Zilretta were no different between both old and young patients.
